SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-014815
Filing Date
2022-08-04
Accepted
2022-08-04 16:40:54
Documents
59
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q algs-20220630.htm   iXBRL 10-Q 3126853
2 EX-31.1 algs-ex31_1.htm EX-31.1 21312
3 EX-31.2 algs-ex31_2.htm EX-31.2 21310
4 EX-32.1 algs-ex32_1.htm EX-32.1 12200
5 EX-32.2 algs-ex32_2.htm EX-32.2 12195
  Complete submission text file 0000950170-22-014815.txt   8552903

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT algs-20220630.xsd EX-101.SCH 50752
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT algs-20220630_pre.xml EX-101.PRE 308459
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT algs-20220630_def.xml EX-101.DEF 172931
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT algs-20220630_lab.xml EX-101.LAB 448920
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT algs-20220630_cal.xml EX-101.CAL 43850
53 EXTRACTED XBRL INSTANCE DOCUMENT algs-20220630_htm.xml XML 1348034
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 221137309
SIC: 2836 Biological Products, (No Diagnostic Substances)